C3i Attended the 2026 Summit4CI

From March 29 to 31, 2026, C3i participated in the Summit for Cancer Immunotherapy (Summit4CI), organized by BioCanRx in Vancouver. This annual event brings together scientists, clinicians, industry leaders, and patient advocates committed to advancing immuno-oncology.

At the event, Jamie Sharp, Director of Business Development at C3i, represented the organization to engage with the teams behind several of the most promising immunotherapy programs.

Discussions focused in particular on a key challenge for the sector: the importance of integrating manufacturing strategy from the very start of a program’s development. Whether it involves CAR-T therapies, NK cells, viral vectors, or other advanced approaches, the needs related to process development, regulatory compliance, scaling up, clinical manufacturing, and commercialization must be anticipated from the earliest stages.

In this fast-changing environment, C3i continues to position itself as an expert and reliable partner, providing the necessary support from development through commercial production, in accordance with GMP.

Participating in Summit4CI 2026 enabled C3i to strengthen its presence in the immunotherapy ecosystem and continue strategic discussions with key players shaping the future of cell and gene therapies.